Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Hoos Explains the Future of Immunotherapy

July 18th 2011

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Schuchter on the Progression of Melanoma Care

July 15th 2011

Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years

Dr. Schuchter on Managing Ipilimumab's Side Effects

July 13th 2011

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Tim Turnham on the Melanoma Research Foundation

July 12th 2011

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Schuchter on the Next Steps in Melanoma Research

July 7th 2011

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Schuchter Limits BRAF Testing to Advanced Melanoma

June 30th 2011

Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma

Dr. Schuchter on Testing for a BRAF Mutation in Melanoma

June 27th 2011

Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

Dr. Infante on the Next Step in Melanoma Research

June 23rd 2011

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Hoos on a Possible Successor Drug to Ipilimumab

June 22nd 2011

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Vismodegib Trial Yields Benefits in BCC patients

June 20th 2011

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Wolchok on Patients That Had to Stop Treatment Early

June 20th 2011

Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early

Dr. Wolchok Explains the Future of Ipilimumab

June 17th 2011

Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab

Dr. Wolchok Describes Candidates for Ipilimumab

June 16th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab

Dr. Chapman on Vemurafenib Combination Therapies

June 16th 2011

Dr. Chapman from Memorial Sloan-Kettering Cancer Center on Vemurafenib Combination Therapies